Table 6 Pathways identified among proteins differentially expressed upon T cell activation in both MS and healthy control samples
Ingenuity canonical pathways | − log(p-value) |
|---|---|
EIF2 signaling | 33.90 |
Regulation of eIF4 and p70S6K signaling | 15.00 |
Coronavirus pathogenesis pathway | 9.48 |
mTOR signaling | 8.18 |
Cytotoxic T Lymphocyte-mediated apoptosis of target cells | 6.81 |
Antiproliferative role of TOB in T cell signaling | 5.95 |
Superpathway of cholesterol biosynthesis | 5.89 |
Protein ubiquitination pathway | 5.68 |
OX40 signaling pathway | 5.64 |
iCOS-iCOSL signaling in T helper cells | 4.60 |
tRNA charging | 4.58 |
Superpathway of serine and glycine biosynthesis I | 4.36 |
Th1 pathway | 4.17 |
Cholesterol biosynthesis I | 3.90 |
Cholesterol biosynthesis II (via 24,25-dihydrolanosterol) | 3.90 |
Cholesterol biosynthesis III (via Desmosterol) | 3.90 |
CTLA4 signaling in cytotoxic T lymphocytes | 3.87 |
PD-1, PD-L1 cancer immunotherapy pathway | 3.74 |
Serine biosynthesis | 3.54 |
Proline biosynthesis I | 3.54 |
Type I diabetes mellitus signaling | 3.52 |
Th1 and Th2 activation pathway | 3.42 |
T helper cell differentiation | 3.34 |
Glucocorticoid receptor signaling | 3.31 |
Purine nucleotides De Novo biosynthesis II | 3.10 |
Th2 pathway | 3.08 |
Primary immunodeficiency signaling | 2.97 |
Th17 activation pathway | 2.97 |
BAG2 signaling pathway | 2.97 |
Crosstalk between dendritic cells and natural killer cells | 2.82 |
Epoxysqualene biosynthesis | 2.75 |
Role of PKR in interferon induction and antiviral response | 2.72 |
Antigen presentation pathway | 2.65 |
Autoimmune thyroid disease signaling | 2.58 |
Calcium-induced T lymphocyte apoptosis | 2.51 |
Superpathway of geranylgeranyldiphosphate biosynthesis I (via Mevalonate) | 2.32 |
Folate transformations I | 2.29 |
Diphthamide biosynthesis | 2.29 |
Cell Cycle: G1/S checkpoint regulation | 2.29 |
Pyrimidine ribonucleotides De Novo biosynthesis | 2.27 |
Methionine degradation I (to Homocysteine) | 2.23 |
CD28 signaling in T helper cells | 2.07 |
Cysteine biosynthesis III (mammalia) | 2.06 |
Regulation of IL-2 expression in activated and anergic T lymphocytes | 2.00 |
Proline biosynthesis II (from Arginine) | 2.00 |
Trans, trans-farnesyl diphosphate biosynthesis | 2.00 |
Allograft rejection signaling | 1.97 |
FAT10 cancer signaling pathway | 1.97 |
T cell exhaustion signaling pathway | 1.95 |
IL-9 signaling | 1.94 |
Role of JAK1, JAK2 and TYK2 in interferon signaling | 1.91 |
Induction of apoptosis by HIV1 | 1.87 |
Assembly of RNA polymerase II complex | 1.83 |
Hematopoiesis from pluripotent stem cells | 1.83 |
Altered T cell and B cell signaling in rheumatoid arthritis | 1.82 |
Mevalonate pathway I | 1.81 |
Tetrahydrofolate salvage from 5,10-methenyltetrahydrofolate | 1.79 |
Folate polyglutamylation | 1.79 |
Nur77 signaling in T lymphocytes | 1.76 |
Pyrimidine ribonucleotides interconversion | 1.74 |
Systemic lupus erythematosus in T cell signaling pathway | 1.73 |
Role of NFAT in regulation of the immune response | 1.70 |
Graft-versus-host disease signaling | 1.69 |
Activation of IRF by cytosolic pattern recognition receptors | 1.64 |
CD27 signaling in lymphocytes | 1.64 |
Lymphotoxin Œ ≤ receptor signaling | 1.64 |
Cell cycle control of chromosomal replication | 1.64 |
Arginine degradation VI (arginase 2 pathway) | 1.63 |
Histidine degradation III | 1.63 |
Citrulline biosynthesis | 1.63 |
Zymosterol biosynthesis | 1.63 |
Dendritic cell maturation | 1.61 |
T cell receptor signaling | 1.58 |
RAN signaling | 1.56 |
Cdc42 signaling | 1.55 |
PKCθ signaling in T lymphocytes | 1.55 |
Aldosterone signaling in epithelial cells | 1.53 |
FAT10 signaling pathway | 1.49 |
Aryl hydrocarbon receptor signaling | 1.46 |
Methylthiopropionate biosynthesis | 1.38 |
Proline degradation | 1.38 |
Acetyl-CoA biosynthesis III (from Citrate) | 1.38 |
Asparagine biosynthesis I | 1.38 |
Alanine biosynthesis III | 1.38 |
Superpathway of methionine degradation | 1.36 |
Caveolar-mediated endocytosis signaling | 1.34 |